These findings suggest that EBNA1 may play an intrinsic role in shaping the TME in EBV+ cHL by increasing CCL20 expression to favour the recruitment of CD4+/FoxP3+ Treg cells that inhibit a tumour-specific immune response. The gene discussed is CD4; the disease is neoplasm.